Allosteric interactions at muscarinic cholinoceptors

Clinical and Experimental Pharmacology and Physiology

Volumn 25, Issue 3-4, 1998, Pages 185-194

  Christopoulos, Arthur ^a   Lanzafame, Alfred ^a   Mitchelson, Fred ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Allosteric interactions; Co operativity; Muscarinic cholinoceptors

Indexed keywords

ALCURONIUM; GALLAMINE; MUSCARINIC RECEPTOR;

ALLOSTERISM; BINDING SITE; COMPETITIVE INHIBITION; CONFORMATIONAL TRANSITION; DISSOCIATION CONSTANT; DRUG MECHANISM; HUMAN; MODEL; REVIEW;

EID: 0031955647     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1681.1998.t01-4-.x     Document Type: Review

References (91)

1. Kenakin T. Pharmacologie analysis of drug-receptor interaction, 3rd edn. Lippincott-Raven Press, New York. 1997.
2. Colquhoun D. The relation between classical and cooperative models for drug action. In: Rang HP (ed.). Drag Receptors. The Macmillan Press Ltd, London. 1973; 149-82.
3. Birdsall NJM, Cohen F, Lazareno S, Matsui H. Allosteric regulation of G-protein-Iinked receptors. Biochem. Soc. Trans. 1995; 23: 108-11.
4. Caulfield MR Muscarinic receptors: Characterization, coupling and function. Pliarmacol. Ther. 1993; 58: 319-79.
5. Monod J, Changeux J-P, Jacob F. Allosteric proteins and cellular control systems. J. Mol. Biol. 1963; 6: 306-29.
6. Proäka J, Tucek S. Mechanism of steric and cooperative actions of alcuronium on cardiac muscarinic receptors. Mol. Pharmacol. 1994; 45: 709-17.
7. Monod J, Wyman J, Changeux J-P. On the nature of allosteric transitions: A plausible model. J. Mol. Biol. 1965; 12: 88-118.
8. Ehlert FJ. Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol. Pharmacol. 1988; 33: 187-94.
9. Stockton JM, Birdsall NJM, Burgen ASV, Hulme EC. Modification of the binding properties of muscarinic receptors by gallamine. Mol. Pharmacol 1983; 23: 551-7.
10. Jakubfk J, Bacâkovâ L, Lisa V, EI-Fakahany EE, Tucek S. Constitutive activity of the M1-M4 subtypes of muscarinic receptors in transfected CHO cells and of muscarinic receptors in heart cells revealed by negative antagonists. FEES Lett. 1995; 377: 275-9.
11. Lee NH, El-Fakahany EE. Allosteric antagonists of the muscarinic acetylcholine receptor. Biochem. Phannacol. 1991; 42: 199-205.
12. Lazareno S, Birdsall NJM. Detection, quantitation, and verification of allosteric interactions of agents with labelled and unlabelled ligands at G protein-coupled receptors: Interactions of strychnine and acetylcholine at muscarinic receptors. Mol. Phannacol. 1995; 48: 362-78.
13. Liillmann H, Ohnesorge FK, Schauwecker GC, Wasserman O. Inhibition of the actions of carbachol and DFP on guinea pig isolated atria by alkane-fci's-ammonium compounds. Eur. J. Phannacol. 1969; 6:241-7.
14. Clark AL, Mitchelson F. The inhibitory effect of gallamine on muscarinic receptors. Br. J. Phannacol. 1976; 58: 323-31.
15. Mitchelson F. Antimuscarinic action of an alkane-to-ammonium compound alone and in combination with (+)-benzetimide. Eur. J. Pharmacol 1975; 33: 237-46.
16. Ehlert FJ. Gallamine allosterically antagonizes muscarinic receptormediated inhibition of adenylate cyclase activity in the rat myocardium. J. Phannacol. Exp. Ther. 1988; 247: 596-602.
17. Lanzafame A, Christopoulos A, Mitchelson F. Interactions of agonists with an allosteric antagonist at muscarinic acetylcholine M2 receptors. Eur. J. Phannacol. 1996; 316: 27-32.
18. Dunlap J, Brown JH. Heterogeneity of binding sites on cardiac muscarinic receptors induced by the neuromuscular blocking agents gallamine and pancuronium. Mol Phannacol 1983; 24: 15-22.
19. Lee NH, El-Fakahany EE. Influence of ligand choice on the apparent binding profile of gallamine to cardiac muscarinic receptors. Identification of three main types of gallamine-muscarinic receptor interactions. J. Pharmacol. Exp. Ther. 1988; 246: 829-38.
20. Waelbroeck M, Robberacht P, De Neef P, Christophe J. Effects of D-tubocurarine on rat cardiac muscarinic receptors: A comparison with gallamine. J. Recept. Res. 1988; 8: 787-808.
21. Kostenis E, Mohr K. Two-point kinetic experiments to quantify allosteric effects on radioligand dissociation. Trends Phannacol. Sei. 1996; 17: 280-3.
22. Ellis J, Seidenberg M. Gallamine exerts biphasic allosteric effects at muscarinic receptors. Mol. Phannacol. 1989; 35: 173-6.
23. Jepsen K, Lüllmann H, Mohr K, Pfeffer J. Allosteric alterations of muscarinic receptors. In: van Zwieten PA, Schonbaum E (eds). Progress in Pharmacology and Clinical Pharmacology, vol. 7/1. Gustav Fischer Verlag, Stuttgart. 1989; 41-4.
24. Christopoulos A, Mitchelson F. Assessment of the allosteric interactions of the bisquaternary heptane-1,7-fc/s-(dimethyl-3'-phthalimidopropy 1)ammonium bromide at Mi and Mi muscarine receptors. Mol. Phannacol. 1994; 46: 105-14.
25. Christopoulos A, Mitchelson F. [3H]-JV-MethylscopoIamine dissociation from muscarine receptors affected by low concentrations of allosteric modulators. Eur. J. Phannacol. (Mol. Phannacol. Sec.) 1995; 290: 259-62.
26. Christopoulos A, Lanzafame A, Ziegler A, Mitchelson F. Kinetic studies of co-operativily at atrial muscarinic Mj receptors with an 'infinite dilution' procedure. Biochem. Pharmacol. 1997; 53: 795-800.
27. Lee NH, El-Fakahany EE. Allosteric interaction at the ml, m2 and m3 muscarinic receptor subtypes. J. Pliarmacol. Exp. Tlier. 1991 ; 256:468-79.
28. Ellis J, Huyler J, Brann MR. Allosteric regulation of cloned ml-m5 muscarinic receptor subtypes. Biochem. Pharmacol. 1991; 42:1927-32.
29. Christopoulos A, Loiacono R, Mitchelson F. Binding of the muscarine receptor antagonist heptane-1,7-Ws-(dirnethyI-3 '-phthalimidopropyl)ammonium bromide at cholinoceptor sites. Eur. J. Pharmacol. (Mol. Pharmacol. Sec.) 1993; 246: 1-8.
30. Tucek S, Musilkova J, Nedoma J, Proaka J, Shelkovnikov SW, Vorlicek J. Positive cooperativity in the binding of alcuronium and /V-methylscopolamine to muscarinic acetylcholine receptors. Mol. Pharmacol. 1990; 38: 674-80.
31. Jakubfk J, Bacâkovâ L, El-Fakahany EE, Tucek S. Subtype selectivity of the positive allosteric action of alcuronium at cloned Mi-Ms muscarinic acetylcholine receptors. J. Pharmacol. Exp. Tlier. 1995; 274: 1077-83.
32. Maa A, Kostenis E, Mohr K. Potentiation by alcuronium of the antimuscarinic effect of W-methylscopoIamine in guinea pig left atria. Eur. J. Pharmacol. 1995; 272: 103-6.
33. Tränkle C, Kostenis E, Burgmer U, Mohr K. Search for lead structures to develop new allosteric modulators of muscarinic receptors. J. Pharmacol. Exp. Ther. 1996; 279: 926-33.
34. Lanzafame A, Christopoulos A, Mitchelson F. Three allosteric modulators act at a common site, distinct from that of competitive antagonists, at muscarinic acetylcholine Mz receptors. J. Pharmacol. Exp. Ther. 1997; 282: 278-85.
35. Hejnovd L, Tucek S, El-Fakahany EE. Positive and negative allosteric interactions on muscarinic receptors. Eur. J. Pharmacol. 1995; 291: 427-30.
36. Pedder EK, Eveleigh P, Poyner D, Hulme EC, Birdsall NJM. Modulation of the structure-binding relationships of antagonists for muscarinic acetylcholine receptor subtypes. Br. J. Pharmacol. 1991; 103: 1561-7.
37. Waelbroeck M. Identification of drugs competing with D-tubocurarine for an allosteric site on cardiac muscarinic receptors. Mol. Pharmacol. 1994; 46: 685-92.
38. Jakubfk J, Bacâkovâ L, Lisa V, El-Fakahany EE, Tucek S. Positive cooperativity between allosteric ligands and acetylcholine and other agonists on muscarinic acetylcholine receptors. Physiol. Res. 1997; 46:2IP.
39. Jakubfk J, Bacâkovd L, Lisa V, El-Fakahany EE, Tucek S. Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol. Pharmacol. 1997; 52: 172-9.
40. Maa A, Mohr K. Opposite effects of alcuronium on agonist and on antagonist binding to muscarinic receptors. Eur. J. Pharmacol. 1996; 305: 231-4.
41. Paton WDM, Rang HP. The uptake of atropine and related drugs by intestinal smooth muscle of the guinea-pig in relation to acetylcholine receptors. Proc. R. Soc. Land. Biol. 1965; 163: 1-44.
42. Li CK, Mitchelson F. The effect of stercuronium on cardiac muscarinic receptors. Eur. J. Pharmacol. 1978; 51: 251-9.
43. Leung E, Mitchelson F. The interaction of pancuronium with cardiac and ileal muscarinic receptors. Eur. J. Pharmacol. 1982; 80: 1-9.
44. Gilani AH, Shaheen F, Christopoulos A, Mitchelson F. Interaction of ebeinone, an alkaloid from Frilillaria imperialis, at two muscarinic acetylcholine receptor subtypes. Life Sei. 1997; 60: 535.
45. Giraldo E, Micheletti R, Montagna E et al. Binding and functional characterization of the cardioselective muscarinic antagonist methoctramine. J. Pharmacol. Exp. Tlier. 1988; 244: 1016-20.
46. Lee NH, El-Fakahany EE. Mixed competitive and allosteric antagonism by gallamine of muscarinic receptor-mediated second messenger responses inNlE-115neuroblastoma cells.J.;vroc/iem. 1989; 53: 1300-8.
47. Roffel AF, Elzinga CRS, Meurs H, Zaagsma J. Allosteric interactions of three muscarine antagonists at bovine trachea! smooth muscle and cardiac Mi receptors. Eur. J. Pharmacol. (Mol. Pharmacol. Sec.) 1989; 172: 61-70.
48. Michel AD, Delmendo RE, Lopez M, Whiting RL. On thé interaction of gallamine with muscarinic receptor subtypes. Eur. J. Phannacol. 1990; 183: 335-45.
49. Roeske WR, Venter JC. The differential loss of [3H]-pirenzepine vs. [3H](-)quinuclidinylbenzilate binding to soluble rat brain muscarinic receptors indicates that pirenzepine binds to an allosteric state of the muscarinic receptor. Biochem. Biophys. Res. Commun. 1984; 118: 950-7.
50. Brunner F, Waelbroeck M, Christophe J. Secoverine is a non-selective muscarinic antagonist on rat heart and brain receptors. Eur. J. Pharmacol. 1986; 127: 17-25.
51. Waelbroeck M, De Neef P, Robbercht P, Christophe J. Inhibitory effects of quinidine on rat heart muscarinic receptors. Life Sei. 1984; 35: 1069-76.
52. Waelbroeck M, Robbercht P, De Neef P, Christophe J. Effects of verapamil on the binding properties of rat heart muscarinic receptors: Evidence for an allosteric site. Biochem. Biophys. Res. Commun. 1984; 121: 340-5.
53. Cohen-Armon M, Henis YI, Kloog Y, Sokolovsky M. Interactions of quinidine and lidocaine with rat brain and heart muscarinic receptors. Biochem. Biophys. Res. Commun. 1985; 127: 326-32.
54. Cohen-Armon M, Kloog Y, Henis YI, Sokolovsky M. Batrachotoxin changes the properties of the muscarinic receptor in rat brain and heart: Possible interaction(s) between muscarinic receptors and sodium channels. Proc. NatlAcad. Sei. USA 1985; 82: 3524-7.
55. Gerry RH, Rauch B, Colvin RA, Adler PNA, Messineo FC. Verapamil interaction with the muscarinic receptor: Stereoselectivity at two sites. Biochem. Phannacol. 1987; 36: 2951-6.
56. Max SI, Liang J-S, Potter LT. Stable allosteric binding of mi-toxin to ml muscarinic receptors. Mol. Phannacol. 1993; 44: 1171-5.
57. Birdsall NJM, Parries T, Gharagozloo P et al. Selective allosteric enhancement of the binding and actions of acetylcholine at muscarinic receptor subtypes. Life Sei. 1997; 60: 1047-52.
58. Kenakin T, Boselli C. Pharmacologie discrimination between receptor heterogeneity and allosteric interaction: Resultant analysis of gallamine and pirenzepine antagonism of muscarinic responses in rat trachea. J. Phannacol. Exp. Ther. 1989; 250: 944-52.
59. Christopoulos A, Mitchelson F. Application of an allosteric ternary complex model to the technique of pharmacological resultant analysis. J. Pharm. Phannacol. 1997; 49: 781-6.
60. Pearce BD, Potter LP. Effects of tetrahydroaminoacridine on MI and Mi muscarine receptors. Neurosci. Lett. 1988; 88: 281-5.
61. Potter LT, Ferrendelli CA, Hanchett HE, Hollifield MA, Lorenzi MV. Tetrahydroaminoacridine and other allosteric antagonists of hippocampal Ml muscarine receptors. Mol. Phannacol. 1989; 35: 652-60.
62. Flynn DD, Mash DC. Multiple in vitro interactions with and differential in v/vo regulation of muscarinic receptor subtypes by tetrahydroaminoacridine. J. Pharmacol. Exp. Ther. 1989; 250: 573-81.
63. Kiefer-Day JS, Campbell HE, Towles J, EI-Fakahany EE. Muscarinic subtype selectivity of tetrahydroaminoacridine: Possible relationship to its capricious efficacy. Eur. J. Phannacol. 1991; 203: 421-3.
64. Mohr K, Tränkle C. Allosteric effects of the alkane-fcis-ammonium compound W84 and of tacrine on [3H]pirenzepine binding at Mi-receptors in rat cerebral cortex. Phannacol. Toxicol. 1994; 75: 391-4.
65. Proäka J, Tucek S. Positive allosteric action of eburnamonine on cardiac muscarinic acetylcholine receptors. Eur. J. Pharmacol. 1996; 305: 201-5.
66. Hu J, Wang S-H, Forray C, El-Fakahany EE. Complex allosteric modulation of cardiac muscarinic receptors by protamine: Potential model for putative endogenous ligands. Mol. Phannacol. 1992; 42: 311-24.
67. Hu J, El-Fakahany EE. Allosteric interaction of dynorphin and myelin basic protein with muscarinic receptors. Plwrmacology 1993; 47:351-9.
68. Jacoby DB, Gleich GJ, Fryer AD. Human eosinophil major basic protein is an endogenous allosteric antagonist at the inhibitory muscarinic M2 receptor. J. Clin. Invest. 1993; 91: 1314-18.
69. Bejeuhr G, Holzgrabe U, Mohr K, Siirig U, von Peterson A. Molecular modelling and synthesis of potent stabilizers of antagonist binding to M-cholinoceptors. Phann. Phannacol. Lett. 1992; 2: 100-3.
70. Bejeuhr G, Blaschke G, Holzgrabe U, Mohr K, Sürig U, Terfloth G. A stable and highly potent hexamethonium derivative which modulates muscarinic receptors allosterically in guinea-pig hearts. J. Phann. Phannacol. 1994; 46: 108-12.
71. Mohr K, Holzgrabe U, Lii H, Tränkle C. On the over-additive antimuscarinic action with atropine of potent allosteric stabilizers of antagonist binding to Mz-receptors. Life Sei. 1993; 52: 564.
72. Bolero Cid MH, Holzgrabe U, Kostenis E, Mohr K, Tränkle C. Search for the pharmacophore of bispyridinium-type allosteric modulators of muscarinic receptors. J. Med. Chem. 1994; 37: 1439-45.
73. Kostenis E, Holzgrabe U, Mohr K. Allosteric effect on muscarinic M2receptors of derivatives of the alkane-fcù-ammonium compound W84. Comparison with bispyridinium-type allosteric modulators. EUT. J. Med. Chem. 1994; 29: 947-53.
74. Kostenis E, Botero Cid HM, Holzgrabe U, Mohr K. Evidence for a multiple binding mode of bispyridinium-type allosteric modulators of muscarinic receptors. Ear. J. Phannacol. 1996; 314: 385-92.
75. Tränkle C, Elis K, \Viese M, Mohr K. Molecular rigidity and potency of bispyridinium type allosteric modulators at muscarinic Mi-receptors. Life Sei. 1997; 60: 1995-2004.
76. Tränkle C, Mohr K. Divergent modes of action among cationic allosteric modulators of muscarinic Ma receptors. Mol. Phannacol. 1997; 51: 674-82.
77. Ellis J, Seidenberg M. Two allosteric modulators interact at a common site on cardiac muscarinic receptors. Mol. Phannacol. 1992; 42:638-41.
78. Tucek S, Proäka J. Allosteric modulation of muscarinic acetylcholine receptors. Trends Phannacol. Sei. 1995; 16: 205-12.
79. Wess J. Mutational analysis of muscarinic acetylcholine receptors: Structural basis of ligand/receptor/G protein interactions. Life Sei. 1993; 53: 1447-63.
80. Lee NH, Hu J, El-Fakahany EE. Modulation by certain conserved aspartate residues of the allosteric interaction of gallamine at the ml muscarinic receptor. J. Phannacol. Exp. Then 1992; 262: 312-16.
81. Leppik RA, Miller RC, Eck M, Paquet J-L. Role of acidic amino acids in the allosteric modulation by gallamine of antagonist binding at the m2 muscarinic acetylcholine receptor. Mol. Plmnnacol. 1994; 45: 983-90.
82. Matsui H, Lazareno S, Birdsall NJM. Probing of the location of the allosteric site on ml muscarinic receptors by site-directed mutagenesis. Mol. Phannacol. 1995; 47: 88-98.
83. Ellis J, Seidenberg M, Brann MR. Use of chimeric muscarinic receptors to investigate epitopes involved in allosteric interactions. Mol. Phannacol. 1993; 44: 583-8.
84. Jakubfk J, Tucek S. Protection by alcuronium of muscarinic receptors against chemical inactivation and location of the allosteric binding site for alcuronium. J. Neurochem. 1994; 63: 11 932-40.
85. Jakubfk J, Tucek S. Positive allosteric interactions on cardiac muscarinic receptors: Effects of chemical modifications of disulphide and carboxyl groups. Ear. J. Phannacol. (Mol. Phannacol. Sec.) 1995; 289: 311-19.
86. Proäka J, Tucek S. Competition between positive and negative allosteric effectors on muscarinic receptors. J. Phannacol. Exp. Tlier. 1995; 48: 696-702.
87. Gerstin EH Jr, Luong T, Ehlert FJ. Heparin, dextran and trypan blue allosterically modulate M2 muscarinic receptor binding properties and interfere with receptor-mediated inhibition of adenylate cyclase. J. Phannacol. Exp. Tlier. 1992; 263: 910-17.
88. Wang SZ, Edmundson R, Zhu SZ, El-Fakahany EE. Selective enhancement of antagonist ligand binding at muscarinic Mi receptors due to receptor uncoupling. Eur. J. Phannacol. 1996; 296: 113-18.
89. Hoare SRJ, Strange PG. Regulation of DI dopamine receptors by amiloride and amiloride analogs. Mol. Pliannacol. 1996; 50:1295-308.
90. Lee JH, Fryer AD, Forray C, El-Fakahany EE. Different mechanisms of antagonism by methoctramine of two neuronal muscarinic receptormediated second messenger responses. J. Phannacol. Exp. Ther. 1989; 251: 992-9.
91. Jakubfk J, Bacdkovd L, Lisa V, EI-Fakahany EE, Tucek S. Activation of muscarinic acetylcholine receptors via their allosteric binding sites. Proc. NallAcad. Sei. USA 1996; 93: 8705-9.